Stroboscopic light stimulation safety within and beyond laboratory settings: Observational evidence and practical guidance
12 affiliations
- 1Sussex Centre for Consciousness Science and School of Engineering and Informatics, University of Sussex, Brighton, United Kingdom
- 2MSB Medical School Berlin, Institute of Neuroscience and Biopsychology for Clinical Application (INBICA), Berlin, Germany
- 3CIRCE - Collaboration for Interdisciplinary Research on Conscious Experience e.V., Teupitz, Germany
- 4UCL Queen Square Institute of Neurology, London, United Kingdom
- 5Department of Neurology, West China Hospital, Sichuan University, Chengdu, China
- 6Macquarie University, Sydney, Australia
- 7Faculty of Social and Behavioural Sciences, Leiden University, Leiden, Netherlands
- 8Centre for the Study of Perceptual Experience, University of Glasgow, Glasgow, United Kingdom
- 9Lumenate Growth Ltd., Bristol, United Kingdom
- 10Audyssey, Llansantffraid, Powys, United Kingdom
- 11Roxiva Innovations Ltd., Sheffield, United Kingdom
- 12Program for Brain, Mind, and Consciousness, Canadian Institute for Advanced Research, Toronto, Canada
Abstract
Stroboscopic light stimulation (SLS) reliably evokes geometric visual hallucinations and, in some contexts, altered-state experiences. Its increasing use in research, public, recreational and exploratory clinical settings creates a need for proportionate safety guidance. The main concern is a visually triggered seizure in a susceptible individual; reported non-epileptic responses include discomfort or distress. We combined a retrospective survey of safety practices and reported events across four laboratories, provider-reported operational data from two commercial SLS platforms, and a focused review of photosensitivity and sensory intolerance. Laboratory contributors reported 20 non-serious events that interrupted or modified participation, with no reported seizures or syncopal episodes. One commercial provider reported nine medically important or otherwise notable events across approximately 3.8 million sessions. The other reported five such events across more than 400,000 sessions. Because commercial adverse-event capture was passive and the laboratory protocols and monitoring procedures were heterogeneous, these figures cannot be used to estimate incidence or establish screening effectiveness. This synthesis informed a provisional Sussex Strobe Safety Screening Questionnaire (4SQ) and a layered, context-specific risk-management approach. The resulting framework distinguishes non-serious tolerability concerns from the principal medical risk of a visually provoked seizure in a susceptible individual, and supports conservative monitored familiarisation exposure, immediate stopping procedures and systematic adverse-event surveillance. The predictive performance of the 4SQ and the effectiveness of these precautions require formal evaluation; absolute SLS risk remains uncertain.
Related
- Navigating HPV vaccination challenges in low-resource settings: Practical strategies for estimating the size of out-of-school girls
- MERIT: A No-Code Platform for Unifying High-Precision Cognitive Assessment Across Laboratory and Real-World Settings
- Sample overlap in genome-wide association meta-analysis: practical comparisons across significance thresholds
- A practical prioritization strategy for vegetation‐focused restoration of anthropogenic wastelands
- Reflections on the ESC consensus statement on inflammation in coronary syndromes: From mechanistic certainty to practical cardiology
BibTeX
@article{schwartzman2026stroboscopic,
title = {{Stroboscopic light stimulation safety within and beyond laboratory settings: Observational evidence and practical guidance}},
author = {David John Schwartzman and Trevor Hewitt and Timo Torsten Schmidt and Josemir Wanderley Sander and Danny Nacker and James Thurbon and Vince Polito and Xaver Funk and Fiona Macpherson and Tom Galea and Gavin Lawson and Jimi Simpson and Romy Beauté and Anil Kumar Seth},
journal = {PLOS One},
year = {2026},
month = oct,
doi = {10.1371/journal.pone.0359958},
url = {https://doi.org/10.1371/journal.pone.0359958},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Stroboscopic light stimulation safety within and beyond laboratory settings: Observational evidence and practical guidance
AU - David John Schwartzman
AU - Trevor Hewitt
AU - Timo Torsten Schmidt
AU - Josemir Wanderley Sander
AU - Danny Nacker
AU - James Thurbon
AU - Vince Polito
AU - Xaver Funk
AU - Fiona Macpherson
AU - Tom Galea
AU - Gavin Lawson
AU - Jimi Simpson
AU - Romy Beauté
AU - Anil Kumar Seth
PY - 2026
DA - 2026/10/14
JO - PLOS One
DO - 10.1371/journal.pone.0359958
UR - https://doi.org/10.1371/journal.pone.0359958
AB - Stroboscopic light stimulation (SLS) reliably evokes geometric visual hallucinations and, in some contexts, altered-state experiences. Its increasing use in research, public, recreational and exploratory clinical settings creates a need for proportionate safety guidance. The main concern is a visually triggered seizure in a susceptible individual; reported non-epileptic responses include discomfort or distress. We combined a retrospective survey of safety practices and reported events across four laboratories, provider-reported operational data from two commercial SLS platforms, and a focused review of photosensitivity and sensory intolerance. Laboratory contributors reported 20 non-serious events that interrupted or modified participation, with no reported seizures or syncopal episodes. One commercial provider reported nine medically important or otherwise notable events across approximately 3.8 million sessions. The other reported five such events across more than 400,000 sessions. Because commercial adverse-event capture was passive and the laboratory protocols and monitoring procedures were heterogeneous, these figures cannot be used to estimate incidence or establish screening effectiveness. This synthesis informed a provisional Sussex Strobe Safety Screening Questionnaire (4SQ) and a layered, context-specific risk-management approach. The resulting framework distinguishes non-serious tolerability concerns from the principal medical risk of a visually provoked seizure in a susceptible individual, and supports conservative monitored familiarisation exposure, immediate stopping procedures and systematic adverse-event surveillance. The predictive performance of the 4SQ and the effectiveness of these precautions require formal evaluation; absolute SLS risk remains uncertain.
SN - 1932-6203
ER -